Eplerenone inhibits UUO-induced lymphangiogenesis and cardiac fibrosis by attenuating inflammatory injury.

Gege Chen, Yi Chang, Yunzhao Xiong, Juan Hao, Lingjin Liu, Ziqian Liu, Hui Li, Panpan Qiang, Yutong Han, Yunqian Xian, Tatsuo Shimosawa, Xiangting Wang, Fan Yang, Qingyou Xu

International immunopharmacology 2022 Jul

filter terms:

Cardiorenal syndrome (CRS) is the leading cause of death associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). However, the underlying mechanisms of CRS are still poorly understood. Here, we studied a CKD model of unilateral ureteral obstruction (UUO) and observed pathological cardiac fibrosis and lymphangiogenesis in 180-day old UUO rats, in which inflammatory injury plays a major role. In addition, treatment of UUO rats with eplerenone, a mineralocorticoid receptor blocker (MRB), significantly reduced cardiac lymphangiogenesis and fibrosis. In conclusion, our experimental results showed that cardiac lymphangiogenesis in long-term UUO rats may be involved in the formation of cardiac fibrosis and that eplerenone can alleviate lymphangiogenesis and cardiac fibrosis by inhibiting inflammation. Copyright © 2022 Elsevier B.V. All rights reserved.

Citation

Gege Chen, Yi Chang, Yunzhao Xiong, Juan Hao, Lingjin Liu, Ziqian Liu, Hui Li, Panpan Qiang, Yutong Han, Yunqian Xian, Tatsuo Shimosawa, Xiangting Wang, Fan Yang, Qingyou Xu. Eplerenone inhibits UUO-induced lymphangiogenesis and cardiac fibrosis by attenuating inflammatory injury. International immunopharmacology. 2022 Jul;108:108759